Abstract
Neuroblastoma, a childhood neoplasm arising from neural crest cells, is characterized by a diversity of clinical behavior ranging from spontaneous remission to rapid tumor progression and death. To a large extent, outcome can be predicted by the stage of disease and the age at diagnosis. However, the molecular events responsible for the variability in response to treatment and the rate of tumor growth remain largely unknown. Over the past decade, transformation-linked genetic changes have been identified in neuroblastoma tumors that have contributed to the understanding of tumor predisposition, metastasis, treatment responsiveness, and prognosis. The Children's Oncology Group recently developed a Neuroblastoma Risk Stratification System that is currently in use for treatment stratification purposes, based on clinical and biologic factors that are strongly predictive of outcome. This review discusses the current risk-based treatment approaches for children with neuroblastoma and recent advances in biologic therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 278-292 |
| Number of pages | 15 |
| Journal | Oncologist |
| Volume | 8 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 12 2003 |
Fingerprint
Keywords
- Immunotherapy
- Neuroblastoma
- Retinoids
- Risk-based therapy
- Tumor biology
ASJC Scopus subject areas
- Cancer Research
- Hematology
Cite this
}
Advances in the diagnosis and treatment of neuroblastoma. / Weinstein, Joanna L.; Katzenstein, Howard M.; Cohn, Susan L.
In: Oncologist, Vol. 8, No. 3, 12.06.2003, p. 278-292.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Advances in the diagnosis and treatment of neuroblastoma
AU - Weinstein, Joanna L.
AU - Katzenstein, Howard M.
AU - Cohn, Susan L.
PY - 2003/6/12
Y1 - 2003/6/12
N2 - Neuroblastoma, a childhood neoplasm arising from neural crest cells, is characterized by a diversity of clinical behavior ranging from spontaneous remission to rapid tumor progression and death. To a large extent, outcome can be predicted by the stage of disease and the age at diagnosis. However, the molecular events responsible for the variability in response to treatment and the rate of tumor growth remain largely unknown. Over the past decade, transformation-linked genetic changes have been identified in neuroblastoma tumors that have contributed to the understanding of tumor predisposition, metastasis, treatment responsiveness, and prognosis. The Children's Oncology Group recently developed a Neuroblastoma Risk Stratification System that is currently in use for treatment stratification purposes, based on clinical and biologic factors that are strongly predictive of outcome. This review discusses the current risk-based treatment approaches for children with neuroblastoma and recent advances in biologic therapy.
AB - Neuroblastoma, a childhood neoplasm arising from neural crest cells, is characterized by a diversity of clinical behavior ranging from spontaneous remission to rapid tumor progression and death. To a large extent, outcome can be predicted by the stage of disease and the age at diagnosis. However, the molecular events responsible for the variability in response to treatment and the rate of tumor growth remain largely unknown. Over the past decade, transformation-linked genetic changes have been identified in neuroblastoma tumors that have contributed to the understanding of tumor predisposition, metastasis, treatment responsiveness, and prognosis. The Children's Oncology Group recently developed a Neuroblastoma Risk Stratification System that is currently in use for treatment stratification purposes, based on clinical and biologic factors that are strongly predictive of outcome. This review discusses the current risk-based treatment approaches for children with neuroblastoma and recent advances in biologic therapy.
KW - Immunotherapy
KW - Neuroblastoma
KW - Retinoids
KW - Risk-based therapy
KW - Tumor biology
UR - http://www.scopus.com/inward/record.url?scp=0038697907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038697907&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.8-3-278
DO - 10.1634/theoncologist.8-3-278
M3 - Review article
VL - 8
SP - 278
EP - 292
JO - Oncologist
JF - Oncologist
SN - 1083-7159
IS - 3
ER -